Organigram Holdings Inc. (NASDAQ:OGI - Free Report) - Alliance Global Partners dropped their Q1 2025 EPS estimates for Organigram in a report released on Wednesday, December 18th. Alliance Global Partners analyst A. Grey now forecasts that the company will post earnings of ($0.04) per share for the quarter, down from their previous forecast of ($0.01). The consensus estimate for Organigram's current full-year earnings is ($0.20) per share. Alliance Global Partners also issued estimates for Organigram's Q2 2025 earnings at ($0.03) EPS, Q3 2025 earnings at ($0.03) EPS, Q4 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.11) EPS and FY2026 earnings at ($0.08) EPS.
Organigram Stock Performance
OGI stock traded up $0.02 during midday trading on Monday, reaching $1.58. 1,105,933 shares of the company's stock traded hands, compared to its average volume of 941,150. Organigram has a 52 week low of $1.25 and a 52 week high of $2.91. The company has a 50-day moving average price of $1.61 and a two-hundred day moving average price of $1.67. The firm has a market capitalization of $199.33 million, a PE ratio of -3.76 and a beta of 1.02.
Organigram (NASDAQ:OGI - Get Free Report) last issued its quarterly earnings results on Wednesday, December 18th. The company reported ($0.04) earnings per share for the quarter, missing analysts' consensus estimates of ($0.03) by ($0.01). Organigram had a negative return on equity of 16.76% and a negative net margin of 45.57%.
Institutional Trading of Organigram
A number of large investors have recently modified their holdings of OGI. Toronto Dominion Bank grew its position in Organigram by 803.7% in the third quarter. Toronto Dominion Bank now owns 16,727 shares of the company's stock worth $30,000 after acquiring an additional 14,876 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Organigram by 40.8% during the 2nd quarter. Renaissance Technologies LLC now owns 816,948 shares of the company's stock valued at $1,258,000 after purchasing an additional 236,700 shares during the last quarter. AdvisorShares Investments LLC raised its holdings in shares of Organigram by 11.8% during the 2nd quarter. AdvisorShares Investments LLC now owns 1,000,126 shares of the company's stock valued at $1,540,000 after buying an additional 105,468 shares in the last quarter. Finally, Tidal Investments LLC lifted its position in Organigram by 8.3% in the 3rd quarter. Tidal Investments LLC now owns 1,948,188 shares of the company's stock worth $3,526,000 after buying an additional 149,171 shares during the last quarter. Institutional investors own 34.63% of the company's stock.
Organigram Company Profile
(
Get Free Report)
Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.
Further Reading
Before you consider Organigram, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organigram wasn't on the list.
While Organigram currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
